--- title: "Pre-market hot trades in US stocks: Alnylam Pharma up 9.59% pre-market; Biodexa Pharmaceuticals down 9.38% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/285344547.md" description: "Alnylam Pharma pre-market rose 9.59%; Biodexa Pharmaceuticals pre-market fell 9.38%; Entravision Communications pre-market rose 74.87%; Easy Electric pre-market rose 68.40%; Avalo Therapeutics pre-market rose 44.96%" datetime: "2026-05-06T09:12:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285344547.md) - [en](https://longbridge.com/en/news/285344547.md) - [zh-HK](https://longbridge.com/zh-HK/news/285344547.md) --- # Pre-market hot trades in US stocks: Alnylam Pharma up 9.59% pre-market; Biodexa Pharmaceuticals down 9.38% pre-market **Pre-market Hot Trades in US Stocks** Alnylam Pharma is up 9.59% in pre-market trading. Based on recent key news: 1. On May 4th, Alnylam Pharma announced a price adjustment in Germany, driving the stock price up. The company adjusted prices following the launch of its ATTR-CM product, and the market reacted positively, leading to a pre-market increase of 9.59%. Source: MT Newswires 2. On May 6th, analysts maintained a rating of "Hold" but did not include it in the top recommendations. Although analysts maintain a "Hold" rating on Alnylam Pharma, its exclusion from the top recommendations indicates a cautious market outlook on its future performance. Source: MarketBeat 3. On May 5th, the market expressed concerns about the concentration of TTR business. Analysis pointed out that Alnylam Pharma's revenue is primarily concentrated in the TTR business, and any competition or challenges could impact its performance. Source: MT Newswires The pharmaceutical industry faces policy adjustments and competitive pressures. Biodexa Pharmaceuticals is down 9.38% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. **Top Gainers in Pre-market US Stocks** Entravision Communications is up 74.87% in pre-market trading. Based on recent key news: 1. On May 5th, Entravision's first-quarter financial report showed a year-on-year revenue increase of 114.4%, reaching $196.97 million, significantly boosting the stock price. The company's net income was $12.36 million, with a GAAP EPS of $0.13, demonstrating strong financial performance. Source: Reuters 2. On May 5th, the company announced a 6% increase in local advertising revenue. Despite an 18% decline in national advertising revenue, overall performance still exceeded market expectations, boosting investor confidence. Source: Company press release 3. On May 5th, management emphasized in the earnings call that although the media division is still incurring losses due to investments and restructuring, the ATS business has achieved scale and profitability, and expectations for future political advertising years have also boosted the stock price. Source: Company earnings call transcript The advertising industry faces structural adjustments and requires attention. Yidianxing is up 68.40% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Avalo Therapeutics is up 44.96% in pre-market trading. Based on recent key news: 1. On May 6th, Avalo Therapeutics announced the successful completion of the primary endpoint of the LOTUS trial, leading to a rise in the stock price. The company also announced a public offering plan, further driving the stock price up 2. On May 5th, Avalo Therapeutics announced a public offering of $375 million at a price of $17.75 per share, expected to be completed on May 7th. Following the announcement, the stock price rose 48.5% in after-hours trading. 3. On May 6th, Benzinga data showed that AVTX closed at $16.26 during regular trading hours, up 18%. Benzinga's stock ranking indicates that AVTX is in a long-term upward trend, with strong consolidation trends in the short and medium term. The biotechnology sector has been active recently, with significant capital inflows ### Related Stocks - [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md) - [BDRX.US](https://longbridge.com/en/quote/BDRX.US.md) - [EVC.US](https://longbridge.com/en/quote/EVC.US.md) - [EZGO.US](https://longbridge.com/en/quote/EZGO.US.md) - [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md) ## Related News & Research - [Thrivent Financial for Lutherans Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY](https://longbridge.com/en/news/287050595.md) - [Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/287033782.md) - [Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?](https://longbridge.com/en/news/286962966.md) - [BUZZ-Relay Therapeutics drops on $175 mln stock offering](https://longbridge.com/en/news/286962133.md) - [Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake](https://longbridge.com/en/news/286825924.md)